Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Date: June 18, 2012
Pages: 75
Price:
US$ 3,995.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GE6DAA280E5EN
Leaflet:

Download PDF Leaflet

Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market. The report identifies the key trends shaping and driving the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Gastrointestinal Stromal Tumors (GIST) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope

The report provides information on the key drivers and challenges of the Gastrointestinal Stromal Tumors (GIST) Therapeutics market. Its scope includes -
  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Gastrointestinal Stromal Tumors (GIST) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Gastrointestinal Stromal Tumors (GIST) Therapeutics market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Gastrointestinal Stromal Tumors (GIST) Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Gastrointestinal Stromal Tumors (GIST) Therapeutics market


Reasons to buy

The report will enhance your decision making capability. It will allow you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market landscape? - Identify, understand and capitalize.
1.1 List of Tables
1.2 List of Figures

2 GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS - INTRODUCTION

2.1 Overview
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology
2.5 Staging of Gastrointestinal Stromal Tumors
2.6 Diagnosis of Gastrointestinal Stromal Tumors
  2.6.1 Computed Tomography Scan
  2.6.2 Barium Swallow
  2.6.3 Magnetic Resonance Imaging or Positron Emission Tomography
  2.6.4 Mutational Analysis
2.7 Treatment of Gastrointestinal Stromal Tumors
  2.7.1 Surgery
  2.7.2 Radiation Therapy
  2.7.3 Chemotherapy
  2.7.4 Targeted Therapy
2.8 Treatment and Management Pattern
2.9 Referral Pathway
2.10 GlobalData Pipeline Report Guidance

3 GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS - MARKET CHARACTERIZATION

3.1 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – Global
3.2 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – Global
3.3 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – The US
3.4 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – The US
3.5 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – The UK
3.6 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – The UK
3.7 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – France
3.8 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – France
3.9 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – Germany
3.10 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – Germany
3.11 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – Italy
3.12 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – Italy
3.13 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – Spain
3.14 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – Spain
3.15 Gastrointestinal Stromal Tumors Market Size (2006–2011) – Japan
3.16 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – Japan
3.17 Drivers and Barriers for the Gastrointestinal Stromal Tumors Market
  3.17.1 Drivers for the Gastrointestinal Stromal Tumors Market
  3.17.2 Barriers for the Gastrointestinal Stromal Tumors Therapeutics Market
3.18 Opportunity and Unmet Need
3.19 Key Takeaway

4 GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS - COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Marketed Product Profile
  4.3.1 Gleevec (imatinib mesylate)
  4.3.2 Sutent (sunitinib malate)
4.4 Key Takeaway

5 GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS - PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Gastrointestinal Stromal Tumors Therapeutics Pipeline Analysis – Pipeline by Clinical Phase of Development
  5.3.1 Gastrointestinal Stromal Tumors Therapeutics – Phase III Clinical Pipeline
  5.3.2 Gastrointestinal Stromal Tumors Therapeutics – Phase II/III Clinical Pipeline
  5.3.3 Gastrointestinal Stromal Tumors Therapeutics – Phase II Clinical Pipeline
  5.3.4 Gastrointestinal Stromal Tumors Therapeutics – Phase I/II Clinical Pipeline
  5.3.5 Gastrointestinal Stromal Tumors Therapeutics – Phase I Clinical Pipeline
  5.3.6 Gastrointestinal Stromal Tumors Therapeutics – Preclinical Phase
5.4 Gastrointestinal Stromal Tumors Therapeutics Pipeline Analysis - Pipeline by Mechanism of Action
5.5 Gastrointestinal Stromal Tumors Technology Trends Analytical Framework
5.6 Molecule Profile for Late-stage Molecules under Clinical Development
  5.6.1 Masitinib
  5.6.2 Nexavar (sorafenib)
  5.6.3 Regorafenib (BAY 73-4506)
  5.6.4 Tasigna (nilotinib)
5.7 Key Takeaway

6 GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS – CLINICAL TRIAL MAPPING

6.1 Clinical Trial Mapping by Country (The US, EU5 and Japan)
6.2 Clinical Trial Mapping by Phase
6.3 Clinical Trial Mapping by Trial Status
6.4 Clinical Trial Mapping Overall Sponsors
6.5 Clinical Trial Mapping by Prominent Sponsors
6.6 Clinical Trial Mapping by Companies

7 GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS - STRATEGIC ASSESSMENT

7.1 Gastrointestinal Stromal Tumors Therapeutics: Implications for Future Market Competition

8 GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS - FUTURE PLAYERS IN THE MARKET

8.1 Introduction
8.2 Company Profiles
  8.2.1 Novartis AG
  8.2.2 AB Science
  8.2.3 Bayer AG
8.3 Gastrointestinal Stromal Tumors Therapeutics Market – Other Future Players

9 GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS - LICENSING AND PARTNERSHIP DEALS

10 GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS - APPENDIX

10.1 Definitions
10.2 Acronyms
10.3 Bibliography
10.4 Research Methodology
  10.4.1 Coverage
  10.4.2 Secondary Research
  10.4.3 Forecasting
  10.4.4 Primary Research
  10.4.5 Expert Panel Validation
10.5 Contact Us
10.6 Disclaimer

LIST OF TABLES

Table 1: Historical Prevalence of Gastrointestinal Stromal Tumors in Seven Major Markets, 2006–2011 (approximate)
Table 2: Forecast Prevalence of Gastrointestinal Stromal Tumors in Seven Major Markets, 2011–2019 (approximate)
Table 3: Occurrence Rate of Symptoms of Gastrointestinal Stromal Tumors, 2010
Table 4: TNM Staging, Gastrointestinal Stromal Tumors, 2011
Table 5: Gastrointestinal Stromal Tumors Therapeutics Market, Global, Revenue ($m), 2006–2011
Table 6: Gastrointestinal Stromal Tumors Therapeutics Market, Global, Forecast ($m), 2011–2019
Table 7: Gastrointestinal Stromal Tumors Therapeutics Market, The US, Revenue ($m), 2006–2011
Table 8: Gastrointestinal Stromal Tumors Therapeutics Market, The US, Forecast ($m), 2011–2019
Table 9: Gastrointestinal Stromal Tumors Therapeutics Market, The UK, Revenue ($m), 2006–2011
Table 10: Gastrointestinal Stromal Tumors Therapeutics Market, The UK, Forecast ($m), 2011–2019
Table 11: Gastrointestinal Stromal Tumors Therapeutics Market, France, Revenue ($m), 2006–2011
Table 12: Gastrointestinal Stromal Tumors Therapeutics Market, France, Forecast ($m), 2011–2019
Table 13: Gastrointestinal Stromal Tumors Therapeutics Market, Germany, Revenue ($m), 2006–2011
Table 14: Gastrointestinal Stromal Tumors Therapeutics Market, Germany, Forecast ($m), 2011–2019
Table 15: Gastrointestinal Stromal Tumors Therapeutics Market, Italy, Revenue ($m), 2006–2011
Table 16: Gastrointestinal Stromal Tumors Therapeutics Market, Italy, Forecast ($m), 2011–2019
Table 17: Gastrointestinal Stromal Tumors Therapeutics Market, Spain, Revenue ($m), 2006–2011
Table 18: Gastrointestinal Stromal Tumors Therapeutics Market, Spain, Forecast ($m), 2011–2019
Table 19: Gastrointestinal Stromal Tumors Therapeutics Market, Japan, Revenue ($m), 2006–2011
Table 20: Gastrointestinal Stromal Tumors Therapeutics Market, Japan, Forecast ($m), 2011–2019
Table 21: Gastrointestinal Stromal Tumors Efficacy Results, Sutent
Table 22: Gastrointestinal Stromal Tumors Therapeutics – Phase III Pipeline
Table 23: Gastrointestinal Stromal Tumors Therapeutics – Phase II/III Pipeline
Table 24: Gastrointestinal Stromal Tumors Therapeutics – Phase II Pipeline
Table 25: Gastrointestinal Stromal Tumors Therapeutics – Phase I/II Pipeline
Table 26: Gastrointestinal Stromal Tumors Therapeutics – Phase I Pipeline
Table 27: Gastrointestinal Stromal Tumors Therapeutics – Preclinical Phase
Table 28: Nexavar Phase II Trial – Summary of Results, 2011
Table 29: Gastrointestinal Stromal Tumors Therapeutics – Clinical Trials by Country, 2012
Table 30: Gastrointestinal Stromal Tumors Therapeutics – Clinical Trials by Phase, 2012
Table 31: Gastrointestinal Stromal Tumors Therapeutics – Clinical Trials by Status, 2012
Table 32: Gastrointestinal Stromal Tumors Therapeutics, Overall Sponsors, 2012
Table 33: Gastrointestinal Stromal Tumors Therapeutics – Prominent Sponsors, 2012
Table 34: Gastrointestinal Stromal Tumors Therapeutics – Companies, 2012
Table 35: Gastrointestinal Stromal Tumors Pipeline, Novartis AG
Table 36: Gastrointestinal Stromal Tumors Pipeline, AB Science
Table 37: Gastrointestinal Stromal Tumors Pipeline, Bayer AG
Table 38: Gastrointestinal Stromal Tumors Therapeutics, Other Future Players
Table 39: Gastrointestinal Stromal Tumors Therapeutics, Global, Deals, 2012

LIST OF FIGURES

Figure 1: Distribution of Gastrointestinal Stromal Tumors
Figure 2: Patient Share of Gastrointestinal Stromal Tumors in the Seven Major Markets, 2011
Figure 3: Gastrointestinal Stromal Tumors Therapeutics – Treatment Algorithm
Figure 4: Referral Pathway for Gastrointestinal Stromal Tumors
Figure 5: Gastrointestinal Stromal Tumors Therapeutics Market, Global, Revenue ($m), 2006–2011
Figure 6: Gastrointestinal Stromal Tumors Therapeutics, Global Market Share ($m), 2011
Figure 7: Gastrointestinal Stromal Tumors Therapeutics Market, Global, Forecast ($m), 2011–2019
Figure 8: Gastrointestinal Stromal Tumors Therapeutics, Global Market Share ($m), 2019
Figure 9: Gastrointestinal Stromal Tumors Therapeutics Market, The US, Revenue ($m), 2006–2011
Figure 10: Gastrointestinal Stromal Tumors Therapeutics Market, The US, Forecast ($m), 2011–2019
Figure 11: Gastrointestinal Stromal Tumors Therapeutics Market, The UK, Revenue ($m), 2006–2011
Figure 12: Gastrointestinal Stromal Tumors Therapeutics Market, The UK, Forecast ($m), 2011–2019
Figure 13: Gastrointestinal Stromal Tumors Therapeutics Market, France, Revenue ($m), 2006–2011
Figure 14: Gastrointestinal Stromal Tumors Therapeutics Market, France, Forecast ($m), 2011–2019
Figure 15: Gastrointestinal Stromal Tumors Therapeutics Market, Germany, Revenue ($m), 2006–2011
Figure 16: Gastrointestinal Stromal Tumors Therapeutics Market, Germany, Forecast ($m), 2011–2019
Figure 17: Gastrointestinal Stromal Tumors Therapeutics Market, Italy, Revenue ($m), 2006–2011
Figure 18: Gastrointestinal Stromal Tumors Therapeutics Market, Italy, Forecast ($m), 2011–2019
Figure 19: Gastrointestinal Stromal Tumors Therapeutics Market, Spain, Revenue ($m), 2006–2011
Figure 20: Gastrointestinal Stromal Tumors Therapeutics Market, Spain, Forecast ($m), 2011–2019
Figure 21: Gastrointestinal Stromal Tumors Therapeutics Market, Japan, Revenue ($m), 2006–2011
Figure 22: Gastrointestinal Stromal Tumors Therapeutics Market, Japan, Forecast ($m), 2011–2019
Figure 23: Drivers and Barriers for Gastrointestinal Stromal Tumor Therapeutics, 2012
Figure 24: Opportunity and Unmet Need in the Primary (Resectable) Gastrointestinal Stromal Tumors Therapeutics Market, 2012
Figure 25: Opportunity and Unmet Need in the Metastatic/Unresectable Gastrointestinal Stromal Tumors Therapeutics Market, 2012
Figure 26: Gastrointestinal Stromal Tumors Therapeutics Market – Strategic Competitor Assessment, 2012
Figure 27: Gleevec Phase III Trial Results – Progression-free Survival
Figure 28: Gleevec Phase III Trial Results – Overall Response Rate
Figure 29: Sutent – Time to Tumor Progression in Gastrointestinal Stromal Tumor Patients
Figure 30: Gastrointestinal Stromal Tumors Therapeutics – Pipeline by Phase of Development, 2012
Figure 31: Gastrointestinal Stromal Tumors Therapeutics – Clinical Pipeline by Mechanism of Action, 2012
Figure 32: Technology Trends Analytical Framework of the Gastrointestinal Stromal Tumors Pipeline, 2012
Figure 33: Technology Trends Analytical Framework of the Gastrointestinal Stromal Tumors Pipeline, 2012
Figure 34: Gastrointestinal Stromal Tumors Therapeutics – Clinical Trials by Country, 2012
Figure 35: Gastrointestinal Stromal Tumors Therapeutics – Clinical Trials by Phase, 2012
Figure 36: Gastrointestinal Stromal Tumors Therapeutics – Clinical Trials by Status, 2012
Figure 37: Gastrointestinal Stromal Tumors Therapeutics – Overall Sponsors, 2012
Figure 38: Gastrointestinal Stromal Tumors Therapeutics – Prominent Sponsors, 2012
Figure 39: Gastrointestinal Stromal Tumors Therapeutics – Companies, 2012
Figure 40: Implications for Future Market Competition in the Gastrointestinal Stromal Tumors Therapeutics Market, 2012
Figure 41: Gastrointestinal Stromal Tumors Therapeutics – Future Players, 2012
Figure 42: GlobalData Market Forecasting Model

COMPANIES MENTIONED

Novartis AG
AB Science
Bayer AG

Ask Your Question

Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: